ArticleBMJ open2026
Research on latent class of multisymptom characteristics and transition mechanism of patients with coronary heart disease after PCI: protocol for a multicentre cross-sectional and prospective longitudinal study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-percutaneous coronary intervention (PCI) patients frequently experience multidimensional symptoms (somatic, psychological, social), yet research remains fragmented. Current evidence lacks integration of dynamic symptom interactions and longitudinal evolution patterns. This study addresses critical gaps by characterising latent symptom classes and transition mechanisms during recovery, accounting for sociodemographic environmental influences across three Chinese provinces. METHODS AND ANALYSIS: A multicentre study combines cross-sectional baseline assessment (T0) with prospective longitudinal follow-ups at 1 month (T1) and 6 months (T2) post-PCI. We will recruit 600 patients presenting with acute coronary syndrome and undergoing their first PCI from six Class A Tertiary Hospitals across Hunan, Jiangsu and Hainan provinces (July 2025-January 2026). Symptom phenotyping will use validated instruments: Patient-Reported Outcomes Measurement Information System-29, Tampa Scale for Kinesiophobia and Gastrointestinal Symptom Rating Scale. Latent profile analysis will identify baseline symptom profiles; latent transition analysis will model probabilities of transitioning between classes over time. Model selection will optimise fit indices (Akaike information criterion/Bayesian information criterion/bootstrap likelihood ratio test bootstrap) and clinical interpretability. Covariate-adjusted analyses will explore sociodemographic and environmental effects on symptom trajectories. ETHICS AND DISSEMINATION: Approved by the University of South China Ethics Committee (2024NHHL037). Written informed consent precedes participation, with data deidentified and securely stored. Findings will be published in peer-reviewed journals following Strengthening the Reporting of Observational Studies in Epidemiology guidelines and presented at international cardiovascular conferences. TRIAL REGISTRATION NUMBER: ChiCTR2500097028.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.